# Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

> **NCT00709371** · PHASE2 · COMPLETED · sponsor: **Orexigen Therapeutics, Inc** · enrollment: 729 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Zonisamide SR placebo/ bupropion SR placebo
- **DRUG:** Zonisamide SR placebo/ bupropion SR 360 mg/day
- **DRUG:** Zonisamide SR 120 mg/day/ bupropion SR placebo
- **DRUG:** Zonisamide SR 360 mg/day/ bupropion SR placebo
- **DRUG:** Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
- **DRUG:** Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day

## Key facts

- **NCT ID:** NCT00709371
- **Lead sponsor:** Orexigen Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-04
- **Final completion:** 2009-07
- **Target enrollment:** 729 (ACTUAL)
- **Last updated:** 2012-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00709371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00709371, "Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00709371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*